Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approval By: CNBC.com News June 10, 2024 at 15:56 PM EDT If approved, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind to enter the market after Leqembi from Biogen and Eisai. Read More >> Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approval By: CNBC.com News June 10, 2024 at 15:56 PM EDT If approved, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind to enter the market after Leqembi from Biogen and Eisai. Read More >>